Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | BT-474 is a human breast cancer cell line established in 1978 by E.Y. Lasfargues and his colleagues. This cell line was isolated from the solid primary invasive ductal carcinoma tissue of a 60-year-old Caucasian female patient. BT-474 cells grow as an adherent monolayer, typically forming dense, multilayered epithelial patches or colonies, and rarely achieve a completely flat, confluent state. Internationally, this cell line is recognized as the preferred foundational in vitro model for HER2-positive (Luminal B subtype) breast cancer. Given its simultaneous high expression of hormone receptors coupled with amplification of the Human Epidermal Growth Factor Receptor (HER2), BT-474 has emerged as a pivotal preclinical targeted cell line model, frequently utilized to evaluate targeted therapies—such as Trastuzumab and Selective Estrogen Receptor Modulators (SERMs)—as well as to screen for novel small-molecule kinase inhibitors. |
| Tissue | Breast; Mammary gland |
| Disease | Invasive Ductal Carcinoma / Breast Cancer |
| Morphology | Epithelial-like; forms cohesive, compact, multilayered colonies |
| Gender | Female |
| Age | 60 years |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on standard global cell repository criteria) |
| Applications | 1. A leading model for investigating downstream signaling mechanisms and amplification pathways associated with HER2/neu (ERBB2); 2. Preclinical drug screening for anti-HER2 targeted therapies, monoclonal antibodies, and antibody-drug conjugates (ADCs); 3. Exploration of the signaling crosstalk networks between estrogen, progesterone, and growth factor receptor pathways; 4. Investigation of hormone-dependent cell proliferation and mechanisms of therapeutic resistance; 5. Establishment of highly reliable subcutaneous breast tumor xenograft models in nude or SCID mice. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C (Liquid nitrogen vapor phase; storage at −70°C results in a rapid and complete loss of viability) |
| Characteristics | |
| Tumorigenic | Yes, forms progressively growing tumors when engrafted into immunocompromised mice or rats. Note: In vivo growth is often enhanced by estrogen supplementation. |
| Karyotype | Aneuploid / Hyperdiploid; modal chromosome distribution center typically ranges around 55. Highly rearranged human karyotype showing complex structural markers. |
| Receptor Profile | 1. HER2/neu (ERBB2) Status: Highly amplified and overexpressed on the cell surface. 2. Estrogen Receptor (ER) Status: Positive. 3. Progesterone Receptor (PR) Status: Positive. |
| Genetic Profile | 1. TP53 Status: Mutated. 2. Isoenzymes: Glucose-6-phosphate dehydrogenase (G6PD) migration pattern is strictly Type B. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Completely aspirate and discard the spent complete culture medium. 2. Gently rinse the cell monolayer with a standard 0.25% Trypsin–0.53 mM EDTA solution to remove residual traces of serum containing active trypsin inhibitors. 3. Aspirate the rinse solution, add 1.0 to 2.0 mL of fresh Trypsin–EDTA solution to completely immerse the cell layer, and allow it to stand undisturbed. 4. Incubate at room temperature or 37°C until the cells round up and detach. Critical Tip: BT-474 cells are highly prone to physical aggregation. While waiting for the cells to detach, never agitate the cells by tapping, vibrating, or shaking the culture flask, as this will result in irreversible cell clumping. 5. Add 6.0 to 8.0 mL of complete growth medium to the culture vessel, and gently resuspend the cells by repeated pipetting to ensure uniform dispersion. 6. Centrifuge the cell suspension at approximately 125 × g for 5 to 7 minutes; carefully aspirate the supernatant, gently resuspend the cell pellet in fresh medium, and then aliquot the suspension into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A low subcultivation ratio of 1:2 to 1:3 is standardly recommended due to its slow, clustered growth kinetics. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 95% Fetal Bovine Serum (FBS) + 5% DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0105 | GFP Stable Cell Line-BT474 | Inquiry |
| CSC-RR00742 | Luciferase Reporter Cell Line - BT474 | Inquiry |
| CSC-RO01440 | OVAL Stable Cell Line - BT474 | Inquiry |
| CSC-RO01693 | GFP/OVAL Stable Cell Line - BT474 | Inquiry |
| CSC-RO01946 | Luc/OVAL Stable Cell Line - BT474 | Inquiry |
| CSC-RO02199 | GFP/Luc/OVAL Stable Cell Line - BT474 | Inquiry |
| CSC-RR01043 | mScarlet/LUC Reporter Cell Line - BT-474 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.